PE20061064A1 - Agentes farmaceuticos que contienen complejos metalicos con contenido de fluoroalquilo y epotilonas - Google Patents
Agentes farmaceuticos que contienen complejos metalicos con contenido de fluoroalquilo y epotilonasInfo
- Publication number
- PE20061064A1 PE20061064A1 PE2006000192A PE2006000192A PE20061064A1 PE 20061064 A1 PE20061064 A1 PE 20061064A1 PE 2006000192 A PE2006000192 A PE 2006000192A PE 2006000192 A PE2006000192 A PE 2006000192A PE 20061064 A1 PE20061064 A1 PE 20061064A1
- Authority
- PE
- Peru
- Prior art keywords
- fluoroalkyl
- content
- pharmaceutical agents
- epothylones
- agents containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Abstract
REFERIDA A AGENTES FARMACEUTICOS PARA APLICACION INTRAVENOSA QUE CONTIENEN: A) AL MENOS UN COMPLEJO METALICO CON CONTENIDO DE FLUOROALQUILO, QUE CONTIENE COMO METAL UN ION DE LOS ELEMENTOS DE LOS NUMEROS ATOMICOS 20 A 29, 39, 42, 44, 57 A 70 U 83 Y QUE PRESENTA UNA CONCENTRACION CRITICA DE FORMACION DE MICELAS MENOR DE 10-3 MOL/L Y UN DIAMETRO HIDRODINAMICO DE MICELAS (2Rh) MAYOR DE 1 NM Y B) AL MENOS UNA EPOTILONA O DERIVADO DE EPOTILONA NATURALES O SINTETICOS, EVENTUALMENTE CON LOS ADITIVOS USUALES EN LA GALENICA. DICHOS AGENTES SON UTILES PARA EL DIAGNOSTICO Y TERAPIA DE TUMORES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005008309A DE102005008309A1 (de) | 2005-02-17 | 2005-02-17 | Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061064A1 true PE20061064A1 (es) | 2006-11-08 |
Family
ID=36123179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000192A PE20061064A1 (es) | 2005-02-17 | 2006-02-16 | Agentes farmaceuticos que contienen complejos metalicos con contenido de fluoroalquilo y epotilonas |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060257322A1 (es) |
EP (1) | EP1848429A1 (es) |
JP (1) | JP2008530157A (es) |
AR (1) | AR052912A1 (es) |
DE (1) | DE102005008309A1 (es) |
DO (1) | DOP2006000038A (es) |
GT (1) | GT200600073A (es) |
PA (1) | PA8663801A1 (es) |
PE (1) | PE20061064A1 (es) |
TW (1) | TW200640456A (es) |
UY (1) | UY29382A1 (es) |
WO (1) | WO2006087145A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568453B (zh) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | 具有螯合型複合微胞之藥物載體及其應用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19603033A1 (de) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
DE19608278A1 (de) * | 1996-02-23 | 1997-08-28 | Schering Ag | Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
DE10066210B4 (de) * | 2000-08-11 | 2008-02-28 | Bayer Schering Pharma Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques |
EP1475105A1 (en) * | 2003-05-09 | 2004-11-10 | Schering AG | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
-
2005
- 2005-02-17 DE DE102005008309A patent/DE102005008309A1/de not_active Withdrawn
-
2006
- 2006-02-06 WO PCT/EP2006/001200 patent/WO2006087145A1/de active Application Filing
- 2006-02-06 JP JP2007555508A patent/JP2008530157A/ja not_active Withdrawn
- 2006-02-06 EP EP06706829A patent/EP1848429A1/de not_active Withdrawn
- 2006-02-14 DO DO2006000038A patent/DOP2006000038A/es unknown
- 2006-02-16 US US11/355,251 patent/US20060257322A1/en not_active Abandoned
- 2006-02-16 PE PE2006000192A patent/PE20061064A1/es not_active Application Discontinuation
- 2006-02-16 UY UY29382A patent/UY29382A1/es not_active Application Discontinuation
- 2006-02-16 GT GT200600073A patent/GT200600073A/es unknown
- 2006-02-17 PA PA20068663801A patent/PA8663801A1/es unknown
- 2006-02-17 AR ARP060100566A patent/AR052912A1/es unknown
- 2006-02-17 TW TW095105537A patent/TW200640456A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DE102005008309A1 (de) | 2006-08-24 |
PA8663801A1 (es) | 2006-12-07 |
WO2006087145A1 (de) | 2006-08-24 |
TW200640456A (en) | 2006-12-01 |
EP1848429A1 (de) | 2007-10-31 |
UY29382A1 (es) | 2006-10-02 |
JP2008530157A (ja) | 2008-08-07 |
GT200600073A (es) | 2007-01-03 |
AR052912A1 (es) | 2007-04-11 |
DOP2006000038A (es) | 2006-08-15 |
US20060257322A1 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Engineered graphene oxide nanocomposite capable of preventing the evolution of antimicrobial resistance | |
Raffa et al. | Discovery of “self-synergistic” spinal/supraspinal antinociception produced by acetaminophen (paracetamol) | |
ES2656762T3 (es) | Método y composiciones para tratamiento del cáncer | |
TW200735890A (en) | Compositions and methods for increasing insulin sensitivity | |
BRPI0900471B8 (pt) | instrumento de grampeamento cirúrgico e método para processar um instrumento para cirurgia | |
DE60203260D1 (de) | Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
MY183402A (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
Hartley et al. | Super‐resolution imaging and quantitative analysis of membrane protein/lipid raft clustering mediated by cell‐surface self‐assembly of hybrid nanoconjugates | |
ATE516391T1 (de) | Verfahren zur herstellung von polyphenylensulfidfilamentgarnen | |
BRPI0403159A (pt) | Produto de tecido orgânico | |
PE20061064A1 (es) | Agentes farmaceuticos que contienen complejos metalicos con contenido de fluoroalquilo y epotilonas | |
Ellermann et al. | Ranolazine prevents levosimendan-induced atrial fibrillation | |
Lee et al. | Lipid emulsions enhance the norepinephrine-mediated reversal of local anesthetic-induced vasodilation at toxic doses | |
Mellert et al. | Tumor suppression by p53: is apoptosis important or not? | |
Bouwman et al. | The mechanism of sevoflurane-induced cardioprotection is independent of the applied ischaemic stimulus in rat trabeculae | |
TH84986B (th) | สารเภสัชวิทยาที่มีสารเชิงซ้อนโลหะที่มีฟลูออโรแอลคิล และอีโพไธโลน | |
Nkhata | The Chinsinga-gate affair: a not-so-subtle threat to academic freedom in Malawi | |
DE10341988A1 (de) | Mehrschichtige Kraftstoff- und Dampfleitung enthaltend Polyphtalamid | |
Xinxin | The “June 4 Syndrome”: Spiritual and Ideological Schizophrenia | |
Abed | Development of orthogonal nanotherapeutics for colorectal cancer treatment | |
Bae et al. | Novel Peptide Micellar Nanoformulation for Treatment of Thrombotic Complications of Sepsis | |
Hoskins | Coalinga chrysotile under the microscope | |
UA38350U (ru) | Способ диагностики нарушения гематоретинального барьера при диабетической ретинопатии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |